Ulteriori informazioni
In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe.
Sommario
List of Principal Authors.- Preface. Introduction.- 1: Mechanisms of fibrogenesis.- 2: Non-invasive markers of liver injury.- 3: Complications of cirrhosis: the relevance of hepatocellular carcinoma.- 4: Controlling necroinflammation of liver with SNMC (Stronger Neo Minophagen C): therapy on interferon non-responders.- 5: Predictive parameters of non-response to standard hepatitis treatment.- 6: Concepts for the treatment of non-responders in hepatitis.- 7: Glycyrrhizin: the molecule and present knowledge of action in various liver diseases.- 8: Dendritic cells in immune responses against hepatitis C virus.- 9: SNMC in the prevention of cirrhosis and hepatocellular carcinoma: Japanese experience.- 10: SNMC in interferon non-responders with chronic hepatitis C: European experience in controlled trials.- Index.
Riassunto
In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe.
